Xenon Pharmaceuticals (XENE) Files Mixed Shelf Registration Statement

Xenon Pharmaceuticals (XENE) Prices 8.47M Share Offering at $29.50/sh

Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a clinical stage biopharmaceutical company, today announced the pricing of its underwritten public offering of 8,474,577 common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to 1,694,915 common shares pursuant to its existing shelf registration statement. The common shares are being offered at a public offering price of $29.50 per common share and the pre-funded warrants are being offered at a price of $29.4999 per pre-funded warrant. The gross proceeds to Xenon from the offering, before deducting underwriting discounts and commissions and other offering... More

Xenon Pharmaceuticals (XENE) PT Raised to $50 at Jefferies

Jefferies analyst Andrew Tsai raised the price target on Xenon Pharmaceuticals (NASDAQ: XENE) to $50.00 (from $28.00) while maintaining a Buy rating.

Xenon Pharmaceuticals (XENE) PT Raised to $45 at Wedbush, Following Clinical Business Update

Wedbush analyst Laura Chico raised the price target on Xenon Pharmaceuticals (NASDAQ: XENE) to $45.00 (from $24.00) while maintaining a Outperform rating.

Xenon Pharmaceuticals (XENE) PT Raised to $45 at Guggenheim, Following Clinical Business Update

Guggenheim analyst Yatin Suneja raised the price target on Xenon Pharmaceuticals (NASDAQ: XENE) to $45.00 (from $30.00) while maintaining a Buy rating.

Xenon Pharmaceuticals (XENE) PT Raised to $44 at Stifel

Stifel analyst Paul Matteis raised the price target on Xenon Pharmaceuticals (NASDAQ: XENE) to $44.00 (from $31.00) while maintaining a Buy rating.

The analyst commented, "We are reiterating our Buy Rating and updating our price target to $44 to reflect the better-than-expected efficacy... More

Pre-Open Stock Movers 10/04: (XENE) (ADVM) (OSUR) Higher; (MRNA) (NEO) (IIVI) Lower (more...)

Today's Pre-Open Stock Movers:

Xenon Pharmaceuticals Inc. (Nasdaq: XENE) 73% HIGHER; reported positive topline results from the Phase 2b X-TOLE clinical trial, which evaluated the clinical efficacy, safety, and tolerability of XEN1101 a differentiated Kv7 potassium channel modulator... More

Xenon's (XENE) X-Tole Data as Good as it Gets with Best-in-Category Efficacy - Analyst

Earlier today, Xenon Pharmaceuticals Inc. (Nasdaq: XENE) reported positive topline results from the Phase 2b X-TOLE clinical trial, which evaluated the clinical efficacy, safety, and tolerability of XEN1101 a differentiated Kv7 potassium channel modulator administered as adjunctive treatment in adult patients with focal... More

Xenon Pharmaceuticals (XENE) Phase 2b 'X-TOLE' Clinical Trial of XEN1101 for the Treatment of Focal Epilepsy Met its Primary Efficacy Endpoint

Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neurology-focused biopharmaceutical company, today reported positive topline results from the Phase 2b X-TOLE clinical trial, which evaluated the clinical efficacy, safety, and tolerability of XEN1101 a differentiated Kv7 potassium channel modulator administered as adjunctive treatment in adult patients... More